Highest Score

Ranked by analysis score
Ranks this page's recent reports by score.
News Corporation
NWSA·Communication Services
A ★★★★Buy
Current$30.03
Target$33.75
Return+12.4%
Oct 20, 2026

News Corp combines durable Dow Jones subscriptions, valuable digital property platforms and rising free cash flow, but property-market cyclicality, legacy media pressure and concentrated voting control constrain its valuation upside.

Score
77
PVH Corp.
PVH·Consumer Discretionary
B ★★★Hold
Current$70.64
Target$90.68
Return+28.4%
Sep 14, 2026

PVH offers unusually cheap ownership of Calvin Klein and TOMMY HILFIGER alongside powerful buyback-driven per-share accretion, but the thesis depends on proving that tariff mitigation and PVH+ can restore durable margins despite structurally modest revenue growth.

Score
77
GitLab Inc.
GTLB·Technology
B ★★★Hold
Current$47.77
Target$60.29
Return+26.2%
Sep 14, 2026

GitLab is evolving from a DevSecOps platform into the enterprise control plane for human-and-agent software delivery, but slowing growth, falling gross margin, heavy SBC and GitHub competition make Flex and Duo monetization essential.

Score
77
Royal Bank of Canada
RY·Financials
B ★★★Hold
Current$207.20
Target$211.20
Return+1.9%
Aug 29, 2026

RBC is the undisputed, highly profitable tollbooth of the global financial system, trading at a demanding, historically elevated premium, meaning investors must remain hyper-vigilant regarding the long-term sustainability of its domestic retail credit quality amidst the looming mortgage renewal cliff.

Score
77
Celldex Therapeutics, Inc.
CLDX·Healthcare
B ★★★Hold
Current$40.38
Target$72.00
Return+78.3%
Aug 26, 2026

Celldex is an exceptionally well-capitalized immunology pioneer positioned to dominate the multi-billion dollar chronic urticaria market with a highly de-risked biological asset, though investors must tolerate extreme binary volatility pending the ultimate validation of its Phase 3 clinical data.

Score
77
Trevi Therapeutics, Inc.
TRVI·Healthcare
B ★★★Hold
Current$17.96
Target$28.20
Return+57.0%
Aug 24, 2026

Trevi holds an undisputed monopoly path in the multi-billion dollar refractory chronic cough market following the collapse of rival P2X3 antagonists, though investors must remain hyper-vigilant regarding binary Phase 3 risks.

Score
77
Delek Logistics Partners, LP
DKL·Energy
B ★★★Hold
Current$53.71
Target$59.10
Return+10.0%
Aug 23, 2026

Delek Logistics provides an elite, highly reliable 8.45% yield backed by irreplaceable Permian infrastructure and accelerating third-party growth, though investors must remain hyper-vigilant regarding its elevated debt burden and susceptibility to interest rate pressures.

Score
77
Graphic Packaging Holding Company
GPK·Consumer Discretionary
B ★★★Hold
Current$11.96
Target$12.65
Return+5.8%
Aug 22, 2026

Graphic Packaging offers a deeply discounted, highly cash-generative play on the secular transition to sustainable fiber packaging, though investors must stomach extreme near-term volatility driven by a crushing debt load, severe input inflation, and the execution risk of a major leadership transition.

Score
77
Diodes Incorporated
DIOD·Technology
B ★★★Hold
Current$99.10
Target$115.00
Return+16.0%
Aug 20, 2026

Diodes is expertly pivoting from commoditized legacy components into the highly profitable tollbooth of AI infrastructure and EV power architectures, though investors must heavily respect the steep historical multiple and wait for the fundamental earnings recovery to fully absorb the premium valuation.

Score
77
Warrior Met Coal, Inc.
HCC·Materials
B ★★★Hold
Current$98.63
Target$106.92
Return+8.4%
Aug 19, 2026

Warrior Met Coal is entering a period of explosive, high-visibility cash flow generation driven by its world-class Blue Creek expansion, but elevated trailing multiples and severe insider selling warrant caution regarding the durability of the global steel pricing cycle.

Score
77
Algonquin Power & Utilities Corp.
AQN·Utilities
B ★★★Hold
Current$5.89
Target$7.00
Return+18.8%
Aug 18, 2026

Algonquin represents a deeply discounted, 4.4%-yielding pure-play utility poised for a structural re-rating upon its 2027 U.S. redomiciliation, provided management can successfully navigate its heavy debt load and lingering California wildfire liabilities without tapping equity markets.

Score
77